A randomized, double-blind, crossover study of phenobarbital and mephobarbital

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology
• Neuroscience

Background:

• Anecdotal evidence suggests mephobarbital may have fewer behavioral side effects than phenobarbital in pediatric patients.
• No prior studies have prospectively evaluated this hypothesis.

Purpose of the Study:

• To compare the efficacy and behavioral side effects of mephobarbital and phenobarbital in children with seizures.
• To test the hypothesis that mephobarbital causes fewer behavioral issues than phenobarbital.

Main Methods:

• Prospective, double-blind, randomized, crossover study design.
• Involved pediatric patients with seizures receiving either mephobarbital or phenobarbital.
• Behavioral side effects assessed using the Abbott Parent Questionnaire.

Main Results:

• Both mephobarbital and phenobarbital demonstrated comparable efficacy in reducing seizure frequency.
• Serum phenobarbital levels were significantly higher during phenobarbital treatment compared to mephobarbital treatment.
• No significant behavioral deterioration was observed with either anticonvulsant, irrespective of administration order.

Conclusions:

• Mephobarbital and phenobarbital are equally effective anticonvulsants for pediatric seizure control.
• Contrary to some clinical beliefs, mephobarbital did not show a significant advantage in behavioral side effect profile over phenobarbital in this study.
• Further research may be warranted to explore nuanced behavioral outcomes or specific patient subgroups.